WALTHAM, Mass.–(BUSINESS WIRE)–Trinity Life Sciences, a leader in global life sciences solutions, is sharing findings from its latest TGaS Landscape report entitled, “Perspectives on Use of Artificial Intelligence/Machine Learning (AIML) for Driving Commercial Performance.” The report, based on responses from 23 different biopharma companies, finds that 90 percent of large pharmaceutical companies initiated AIML projects in 2020 compared to 60 percent of emerging biopharma companies.
“AIML is something that biopharma companies KNOW they should be doing. They often try an ad hoc project at the end-of-the-year with last minute budget, but they really want and need to think about how it fits into the overall strategy and downstream operations”
Marketing mix, patient identification and healthcare practitioner targeting were the most frequently sited use cases for AIML within large pharmaceutical companies, while marketing mix, patient identification and patient journey are the most mentioned within emerging companies.
The report covers the adoption, capabilities, perceptions and use cases of AIML within pharmaceutical companies and is the first report from the newly formed TGaS AIML Solution.
“AIML is something that biopharma companies KNOW they should be doing. They often try an ad hoc project at the end-of-the-year with last minute budget, but they really want and need to think about how it fits into the overall strategy and downstream operations,” said Steve Laux, Vice President, Artificial Intelligence Solution for TGaS Advisors, a division of Trinity. “The pharma industry is slightly behind other industries in adopting AIML and it is not without good reason. The industry has lots of complex and siloed data, regulatory issues and HIPAA constraints, but the inflection point for using AIML is now. Our benchmarking Solution is perfect for companies that are ready to thoughtfully execute on an integrated AIML plan. Understanding lessons learned from peers in real-time is a valuable tool.”
With a roster of large, emerging and precommercial life sciences companies, TGaS Advisors, a division of Trinity, provides robust comparative intelligence and collaborative network membership services.
Media interested in receiving a copy of the report should contact Elizabeth Marshall at EMarshall@trinitylifesciences.com.
About Trinity Life Sciences
Trinity Life Sciences is a trusted strategic partner, providing evidence-based solutions for the life sciences. With over 20 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.
Trinity Life Sciences
Source Business Wire Health: Pharmaceutical News Read More